|Videos|February 1, 2017

Improving Hepatitis C Incidence in the US

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), discusses the CDC’s HCV universal birth cohort testing program.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), discusses the CDC’s HCV universal birth cohort testing program.

Interview Transcript (slightly modified for readability)

“The [CDC] has implemented universal birth cohort testing, so anyone born between 1945 and 1965 should be tested for hepatitis C virus at least once despite any risk factors. Of course if someone has risk factors such as intravenous drug use [or] incarceration, those people should be tested as well.

We’re hoping that [with] universal testing recommendations, people won’t have to ask their doctors to be tested, it will be automatic, and they could know their status that way. It’s really helpful for physicians and health practitioners to adhere to those recommendations, and even if they think that the person in front of them may not have risk factors, if [the patient is] born between the years of 1945 and 1965 to at least test them once, because 75% of all hepatitis C infections in the US are in people who are born in that 20-year timeframe; [therefore], it’s really important for that group to be aware of their status.

Also, I know that it’s difficult, [as] I’m a clinician myself, to take time out of your busy schedule. You have so many things to do, there are so many recommendations in a 15-minute visit, but this would be very, very helpful to help us get people into treatment for what is now a completely treatable chronic disease and hopefully lower the incidences of liver cirrhosis, failure and transplantation here in the US.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.